From 3rd to 5th July, the 15th China Dairy Industry Conference, the 2024 China Dairy D20 Summit and the China Dairy Industry Exhibition were held in Wuhan, Hubei Province. During the event, the China Dairy Association formally announced the list of “Major Scientific and Technological Innovation Achievements in the Dairy Industry”. Synaura Biotech was honoured with the “2024 Major Scientific and Technological Innovation Achievement Award in Dairy” for its project “Breakthrough Production Technology and Application of Human Milk Oligosaccharides (HMOs)”, once again receiving high recognition from the industry.

The ‘Major Scientific and Technological Innovation Achievement Award in Dairy Industry’ aims to fully explore and showcase outstanding achievements in dairy industry innovation, foster a favourable innovation ecosystem, promote the application and dissemination of scientific and technological innovations, advance technological progress and industrial upgrading within the sector, and enhance the overall competitiveness of the dairy industry.

Certificate for the 2024 Major Scientific and Technological Innovation Achievement Award in the Dairy Industry

As China's leading domestic HMO producer, Synaura Biotech employs advanced synthetic biology techniques to achieve efficient and safe HMO production through microbial fermentation. The bacterial strains undergo rigorous screening and safety assessments, meeting National Health Commission standards and establishing a robust foundation for exceptional product quality. Synaura Biotech is wholly committed to advancing compliant domestic production. With an ingenious spirit, it continuously refines production processes and perfects products, striving to deliver HMOs characterised by uniform particle size, high purity, purity without odour, and exceptional value for money. Authoritative third-party testing has confirmed that Synaura HMO possesses the same structural composition as breast milk HMO*. Extensive customer validation has demonstrated that Synaura's HMOs have gained widespread market recognition for their exceptional quality, ease of application, and adaptability to diverse production methods including dry and wet processes. This accolade not only acknowledges Synaura's relentless exploration and innovation within the HMO field but also serves as compelling evidence of its immense potential in driving technological advancement and spearheading industrial upgrading within the sector. Looking ahead, Synaura Biotech remains steadfast in its commitment to deepening expertise within the HMO domain. Through continuous exploration of novel technologies and methodologies, the company will deliver increasingly superior products and services. This endeavour aims to bolster the high-quality development of China's dairy industry and contribute sustainably to the nation's health objectives.

*The verification results are derived from authoritative third-party scientific data.